(IPSS) were collected. Patients with prostate glands 80ml and LUTS related to BPH were retrospectively included in the analysis. Patients were matched and three groups of 50 patients treated with PVP, GreenLEP or OP were compared.
INTRODUCTION AND OBJECTIVES:
Open simple prostatectomy has been a traditional approach for the treatment of prostates larger than 100 grams, however is associated with a significant risk for complications. In the past years, the role of robotic simple prostatectomy (RSP) in the surgical treatment of BPH has been increasing. RSP is associated with reduced blood loss and fewer blood transfusions, lower reoperation rates and a shorter hospital stay in comparison to open approach. Herein, we report the results of our series of RSP.
METHODS: From May 2011 to September 2016, 129 consecutive men underwent transvesical RSP at the University of Southern California. Baseline demographics, pathology data, perioperative complications, 90-d complications, and functional outcomes were assessed. RESULTS: Median age was 70 yr (range: 52-89), BMI was 28.2 kg/m2(range:16.4-48), baseline International Prostate Symptom Score (IPSS) was 27 (range: 3-35), prostate volume was 137.5ml (range: 53.8-300), postvoid residual (PVR) was 247.5ml (range: 27-645), maximum flow rate (Qmax) was 8ml/s (range:0-24), and preoperative PSA was 6.15 ng/ml (1.9-56.3). Forty-eight patients were catheter dependent before surgery. Median operative time was 225min (135-400), estimated blood loss was 100ml (range: 10-1000), and hospital stay was 3 d (range: 1-21). There were no intraoperative complications, no conversions to open surgery and only 1 patient (0.8%) required blood transfusion. Six patients had a concomitant robotic diverticulectomy and 5 patients had concomitant cystolithotomy. Final pathology revealed prostate cancer in 7 patients (5.4%). Six patients experienced Clavien 3 complications (clot retention, n¼3; bladder neck contracture, n¼1; pulmonary embolism, n¼2) . Median postoperative IPSS was 7.5 (P < 0.001), PVR was 6 (p < 0.001) and Qmax was 19.5 (p<0.001). Median follow-up was 7 months (2-61).
CONCLUSIONS: RSP is a safe and effective for treatment of BPH. Functional outcomes are excellent, with statistically significant improvement of IPSS, Qmax and PVR.
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